Because the proliferation of estrogen-sensitive breast cancer cells can be managed by ERα antagonists, endocrine-related therapy using ERα antagonists such as tamoxifen has been performed for years for patients with ERα-positive breast cancer [4]. This evidence concerns the gene ESR1 and breast carcinoma.